As inflammatory mediators involved in myocardial injury and fibrosis, soluble ST2 and galectin-3 were recommended for additive risk stratification of HF patients in the latest guideline (class II b, evidence level B) (6). This evidence concerns the gene LGALS3 and hydrops fetalis.